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The control of acute cisplatin-induced emesis - a comparative study of
granisetron and a combination regimen of high-dose metoclopramide and
dexamethasone
B. Chevallier, on behalf of The Granisetron Study Group*
Service de Medicine Interne et Chimiotherapie, Centre Henri Becquerel, Rouen Cedex 76038, France.
Summary The anti-emetic efficacy and safety of granisetron, a highly selective and potent 5-HT3 receptor
antagonist, was compared with that of high-dose metoclopramide plus dexamethasone in 281 patients due to
receive single-day cisplatin chemotherapy (,>49 mg m-). In this single-blind, multicentre study, granisetron
(40 1tg kg-') was administered as a single prophylactic 5-min infusion. Dexamethasone (12 mg) was
administered as a 30-min infusion followed by a loading dose of 3 mg kg-' metoclopramide. A maintenance
dose ofmetoclopramide 4 mg kg-' was then infused over 8 h. A single prophylactic dose of granisetron was as
effective as the combination regimen in the prevention of cisplatin-induced emesis. Of 143 granisetron-treated
patients, 100 (70%) were complete responders (no vomiting and no or only mild nausea) compared with
93/138 (67%) patients who received the comparator regimen. Twenty-three percent of granisetron-treated
patients experienced one of more adverse events compared with 33% of patients in the comparator group. No
extrapyramidal reactions were reported in the granisetron group compared with 13 in comparator-treated
patients (8%). This difference was significant (P<0.05). The commonest adverse event in the granisetron
group, headache (9.8%) described by the majority of patients as mild, was significantly higher than that
reported in the comparator group (3% P = 0.02). Granisetron appears to be a safe and effective agent which
can be used as a single agent for the prophylaxis of cisplatin-induced emesis. The simplicity of administration,
a single 5-min infusion prior to chemotherapy, and the lack of somnolence or extrapyramidal reactions offer
clear advantages over the comparator combination regimen.
The use of cytostatic agents for the treatment of malignant
disease is associated with a number of undesirable side
effects, the most distressing of which has been reported to be
nausea and vomiting (Coates et al., 1983).
This form of emesis may have a significant effect on the
patient's well being, quality of life and compliance with
further courses of therapy (Laszlo, 1983). Acute cytostatic-
induced emesis (that occurring within 24h of the admini-
stration of chemotherapy) varies in incidence, severity and
duration. The emetogenicity of the chemotherapeutic agent
and a number of patient characteristics - such as sex (Roila
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et al., 1985), a previous history of nausea and vomiting from
any cause (Leventhal et al., 1988; Andrykowski et al., 1985),
alcohol intake (D'Acquisto et al., 1986) and age (Morrow,
1982) - will all determine the susceptibility to cytostatic-
induced nausea and vomiting.
The use of anti-emetic agents to control cytostatic-induced
nausea and vomiting began with the use of single anti-emetic
agents such as the dopamine antagonists, which include the
phenothiazines (e.g. prochlorperazine) or the benzamide
derivatives (e.g. metoclopramide). When used alone, these
agents fail to adequately control emesis in up to 60% of
patients (Moertel & Reitemeier, 1969; Bardfield, 1966). This
led to the development of combination anti-emetic regimens,
where the classical dopamine antagonists were combined with
other agents with little inherent anti-emetic activity, such as
benzodiazepines or corticosteroids or both. Anti-emetic con-
trol was improved, but not substantially.
Gralla et al. (1981) were the first to use high doses of
metoclopramide for the prevention of emesis and demon-
strated improved anti-emetic efficacy of this agent used in
this way, especially in patients receiving high-dose cisplatin
containing regimens where up to 40% of patients could be
controlled with metoclopramide alone. Combination with
corticosteroids (Grunberg et al., 1986) further improved con-
trol and the addition of a benzodiazepine such as lorazepam
was shown to improve the subjective effectiveness of the
combinations (Kris et al., 1985a) and up to 60% of patients
could now be completely controlled (Kris et al., 1987). How-
ever, the use of these regimens is associated with a number of
side effects such as extrapyramidal reactions (Kris et al.,
1983) and sedation. In addition, they were cumbersome and
often inconvenient to administer.
The recognition by Miner and Sanger (1986) that high-
dose metoclopramide exerted its anti-emetic effect via
antagonism of the 5-HT subtype 3 receptor led to the
development of the highly selective 5-HT3 receptor anta-
gonist, granisetron. Early clinical studies have demonstrated
the significant anti-emetic efficacy of granisetron when used
as a single prophylactic agent, given as a single dose, to
control emesis associated with the use of both moderately
emetogenic chemotherapeutic agents (Smith, 1990) and high-
dose cisplatin (Soukop, 1990). Complete control of emesis
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was achieved in up to 81% and 60% of patients respectively.
The use of granisetron was not associated with extra-
pyramidal reactions or somnolence and the drug was
generally well tolerated with the most frequent side effect
being mild headache.
A comparative study has demonstrated the clear super-
iority of granisetron over a combination regimen of
chlorpromazine and dexamethasone in the prophylaxis of
moderately emetogenic cytostatic-induced emesis, where the
complete response rate for each treatment group was 70%
and 49% respectively (Marty, 1990).
This study was undertaken to compare the efficacy and
safety of granisetron with those of a combination anti-emetic
regimen containing high-dose metoclopramide plus dex-
amethasone used according to a recommended schedule
(ABPI Data Sheet Compendium 1989-1990).
Patients and methods
Patients
The study was conducted at 28 centres in four countries
(France, Switzerland, UK and West Germany). Patients elig-
ible for selection into this study were inpatients due to
receive cisplatin-containing chemotherapy for the first time
for the treatment of malignant disease. The chemotherapy
was to be administered on a single day and cisplatin was to
be administered at a minimum dose of > 49 mg m2.
Patients were excluded from the study if they had marked
hepatic or renal dysfunction, active gastric ulceration, gastric
compression or were suffering from acute or chronic nausea
or vomiting.
All patients gave their informed consent to participate in
the study and were free to withdraw at any time. The study
was carried out in accordance with the declaration of Hel-
sinki 1964 and its amendments of Tokyo (1975) and Venice
(1983). Approval from appropriate ethical review committees
was also obtained.
Study design
The study was a single-blind comparison of granisetron and
a standard antiemetic combination regimen containing high-
dose metoclopramide and dexamethasone. Patients were ran-
domly allocated to each treatment group according to a code
generated by SmithKline Beecham Pharmaceuticals and were
blind to treatment.
Anti-emetic therapy
Granisetron was given as a single 40 iLg kg-' dose, admini-
stered as a 5-min infusion which was completed 5 min prior
to the infusion of chemotherapy. Two further doses of
40 pg kg-I were permitted for the treatment of breakthrough
nausea and vomiting occurring within the first 24 h after
chemotherapy and these were given at the discretion of the
attending physician. The second or third dose could be
administered no sooner than 10 min after the previous one.
Any subsequent nausea and vomiting were treated with con-
ventional anti-emetics of the physician's choice.
Dexamethasone was given at a dose of 12 mg infused over
a period of 30 min followed immediately by a loading dose of
3 mg kg-' metoclopramide given over a period of 30 min.
This procedure was completed 5 min before the start of the
chemotherapy infusion. A maintenance dose of metoclo-
pramide 4 mg kg-' was administered as an infusion over a
period of 8 h. Patients in this group were given a standard
anti-emetic therapy of the physician's choice for break-
through nausea and vomiting.
On discharge from hospital all patients were given stan-
dard anti-emetics of the physician's chice, for use at home
when necessary.
Cytostatic therapy
All patients were to receive cisplatin as chemotherapy at a
minimum dose of 49 mg m-2 given as an infusion over
periods of up to 6 h, on a single day, with or without other
chemotherapy agents. Patients were naive to chemotherapy.
Efficacy assessments
Patients were asked to give a subjective assessment of nausea
(rated as none, mild, moderate or severe) and vomiting. This
was recorded for the 6-h period prior to initiation of treat-
ment and assessments were repeated at 6, 12, 18 and 24 h
after the start of treatment. Upon discharge, patients were
asked to make global assessments of nausea and vomiting,
once a day for the subsequent 6 days, until the follow-up
visit.
Vomiting episodes were counted and an emetic episode
constituted either a vomit or retch (vomit not producing
fluid). In addition, both the physician and patient made a
global assessment of efficacy at the end of the first 24-h
period rating the overall control of nausea and vomiting as
very good, good, average, poor or very poor.
Clinical and laboratory monitoring
Blood pressure, pulse rate and temperature were recorded at
screening examination (1-14 days prior to the day of study),
immediately prior to administration of the anti-emetic and
then at 6, 12, 18 and 24 h after the start of the cisplatin
infusion. An ECG recording was made at screening. The
clinician assessed the patient's state of alertness and general
well being at these times and also at the start of cisplatin
therapy and 3 h later. Blood and urine samples were taken
for laboratory analysis at screening, before drug administra-
tion on the study day and 24 h later. A follow-up assessment
was made after 7 days. Data obtained were compared with
predetermined normal ranges for each parameter and also
with the predose value.
Adverse events
Adverse event occurrence was determined by asking the
patient whether they felt different in any way before the
adminsitration of anti-emetic and then at 6 and 24 h after the
start of the cisplatin infusion, and again at the follow-up visit
7 days later. Adverse events were also recorded spon-
taneously by the physician who was asked to record the
severity, outcome and treatment given. The physician was
also required to give an assessment of the causality of the
adverse event in relation to the study treatment. Adverse
events were analysed for frequency and serious adverse
events (defined as any event which is fatal, life threatening,
disabling or incapacitating; or results in hospitalisation, pro-
longs hospital stay or is associated with congenital abnor-
mality, carcinoma or overdose) were identified.
Presentation ofresults
Patient's response to anti-emetic therapy was classified ac-
cording to the following schedule:
Complete responder Patients who experienced no emetic
episodes and had no or only mild nausea in the 24 h after the
administration of chemotherapy.
Major responder Patients who experienced one emetic
episode or, if no emesis occurred, recorded moderate to
severe nausea in the first 24 h.
Minor responder Patients who experienced two to four
emetic episodes in the first 24 h irrespective of the incidence
of nausea.
Failure Patients who experienced more than four emetic
episodes in the first 24h irrespective of nausea.178 B. CHEVALLIER
The complete and major responder categories were com-
bined to define the major efficacy.
Statistical analysis was performed with either the chi-
squared or Cox log rank test, with a 2-sided significance level
of 5% regarded as being significant.
Results
Two hundred and eighty-one patients participated in the
study (183 males and 98 females). A summary of demo-
graphic details are presented in Table I. One hundred and
forty-three patients received anti-emetic treatment with
granisetron and 138 with the comparator regimen of meto-
clopramide combined with dexamethasone. The groups were
well matched in terms of sex and other demographic
parameters. The mean dose of cisplatin was 86 mg m2
(range 20-195mgm2) in the granisetron-treated group and
85 mg m-2 (range 20-201 mgm-2) in the comparator group.
Efficacy over 24 h
The 24-h efficacy response for patients in each treatment
group is presented in Figure 1. One hundred patients (70%)
in the granisetron group and 93 patients (67%) in the com-
Table I Summary ofdemographic data for all patients
Treatment group
Dexamethasonel
Granisetron metoclopramide
n n
Total no. patients 143 138
Sex
Male 99 84
Female 44 54
Race
Caucasian 139 133
Other 4 5
Age (years)
Mean 56.6 54.8
Min 17 17
Max 82 82
s.d. 11.63 12.68
Height (m)
Mean 1.7 1.7
Min 1.4 1.4
Max 1.9 1.9
s.d. 0.1 0.1
Weight (kg)
Mean 63.7 65.2
Min 42 35
Max 101 109
s.d. 11.6 13.7
parator group were complete responders and experienced no
emetic episodes and no more than mild nausea. This
difference was not significantly different (P>0.05). The
number of failures in the comparator group was higher with
14 patients (10.1%) experiencing more than four emetic
episodes compared with only seven patients (4.9%) in the
granisetron group.
There was no statistical difference in the time to first
nausea (P = 0.08), emetic episode (P = 0.49) or less than
complete response (P = 0.18) between the two treatment
groups.
Efficacy by dose ofcisplatin
Patients' reponses to anti-emetic therapy were analysed by
the dose of cisplatin which they received. These data are
presented in Figures 2 and 3. There was no difference in
efficacy by responder category with respect to cisplatin dose
in granisetron or comparator-treated patients (P> 0.05).
Use ofadditional anti-emetic
One hundred and thirteen patients (79%) in the granisetron
group and 111 patients (80%) in the comparator group
received no additional therapy for breakthrough nausea and
vomiting. Where additional therapy was given there was no
statistical difference in the time to first use of rescue therapy
between the groups (P = 0.14).
In the granisetron group, 30 patients (20%) received one
additional dose of granisetron which produced improvement
or resolution of symptoms in 26 patients (87%). Where a
second additional dose was given (eight patients) symptoms
were resolved or improved in 62%. During the first 24h,
rescue treatment with conventional anti-emetics was given to
4% of patients in the granisetron group and 6% of patients
in the comparator group.
Global efficacy rating
Global efficacy of the anti-emetic treatment was rated as
good or very good by 81% of patients who had received
granisetron and by 79% of patients who had received the
comparator regimen. This was not significantly different.
Clinicians rated the treatment as good or very good in 85%
and 77% of patients in the respective groups.
Efficacy over 7 days
At the end of the 7-day study period 51 patients (36%) in the
granisetron group and 65 patients (47%) in the comparator
group remained complete responders. This difference was not
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significant. In 72% of patients receiving granisetron and 80%
of patients receiving metoclopramide/dexamethasone com-
bination, no additional anti-emetic therapy was required for
the total duration of the study.
Clinical and laboratory monitoring
Mean changes in pulse rate, blood pressure and temperature
were small and were not significantly different between
groups. At no time did the investigators rate fewer than 79%
of patients in the granisetron group and 73% of patients in
the comparator group as well. Alertness varied with the
patients' sleep patterns and there was no discernable
difference between the two groups. Analysis of laboratory
investigations again revealed no clinically significant changes
in parameters in either group of patients.
Adverse events
During the 7-day period of study one or more adverse events
were reported in 33 patients (23%) in the granisetron group
and 45 patients (33%) in the metoclopramide/dexamethasone
group. This was not statistically different (P = 0.07) (Table
II). Headache was reported significantly more frequently in
the granisetron group with 14 patients (9.8%) experiencing
this compared to four patients (2.9%) in the comparator
group (P = 0.02). This was the commonest adverse event in
this treatment group. Headaches were usually mild and
resolved either spontaneously or in response to treatment
with a mild analgesic such as paracetamol. Other adverse
events occurring in three or more patients in this group were
diarrhoea and constipation. Significantly more patients in the
comparator group reported diarrhoea, 7.2% compared to
2.1% in the granisetron group (P = 0.04) and somnolence
5.1% compared to 0.7% (P = 0.03) than in the granisetron
group. In addition there were significantly more extra-
pyramidal reactions (including extrapyramidal syndrome,
dyskinesia, trismus and CNS stimulation) in the comparator
group (n = 13) than in the granisetron group where none
were reported (P<0.05).
Two patients in the granisetron group experienced serious
adverse events during the 7-day course of the study. One
patient experienced dyspnoea which resulted in the patient's
death but was considered to be unrelated to granisetron
therapy. Another reported severe buccal cavity haemorrhage
secondary to malignant involvement which was again con-
sidered to be unrelated to therapy with granisetron. Four
patients in the comparator group experienced serious adverse
events. One patient had dyspnoea, tachycardia and pericar-
ditis, a second a transient ischaemic attack, and the third
acute respiratory distress and renal insufficiency. None of
Table II Commonest adverse events reported in each treatment
group
Treatment group
Granisetron Metoclopramidel
dexamethasone
n (%) n (%)
Total no. patients 143 100 138 100
Patients with one or 33 23 45 33
more adverse event
Headache 14 9.8 4 2.9b
Diarrhoea 3 2.1 10 7.2a
Constipation 3 2.1 - -
Agitation - - 4 2.9
Anxiety - 4 2.9
CNS stimulation - - 7 5.1c
Somnolence 1 0.7 7 5.1
Extra pyramidal - - 2 1.4
syndrome
Trismus - 2 1.4
Dyskinesia - - 2 1.4
Hypertension 1 0.7 5 3.6
Hypotension - - 3 2.2
ap = 0.02; bp = 0.04; 'P= 0.006.
these events were thought to be related to anti-emetic
therapy. A fourth patient experienced a severe extra-
pyramidal reaction which was considered to be related to
treatment with metoclopramide.
Discussion
The pattern ofemesis following chemotherapy is variable and
is dependent on several factors, including the chemo-
therapeutic agent, the patient's previous history of nausea
and vomiting, the patient's previous experience of chemo-
therapy and other patient characteristics (Roila et al., 1985;
Levanthal et al., 1988; Andrykowski et al., 1985; D' Aequisto
et al., 1986; Morrow, 1982). Nausea and vomiting occurring
the first 24 h following chemotherapy (acute emesis) is of
particular importance in determining the pattern of emesis.
Patients experiencing poor control of acute emesis are more
likely to experience delayed emesis (nausea and vomiting
after the first 24 h) than patients who are protected during
this period (Kris et al., 1985b; Roila et al., 1991). Initial
control of acute emesis is therefore of importance with drugs
known to cause delayed emesis, such as cisplatin. In addition,
patients who suffer severe acute or delayed emesis are more
likely to suffer anticipatory nausea and vomiting prior to
receiving repeat cycles of chemotherapy (Morrow, 1982)
which may lead to the patient delaying or refusing further
courses of potentially curative treatment (Wilcox et al.,
1982). Gaining control of emesis in the first 24-h period
following chemotherapy can, therefore, improve the likeli-
hood of successful management of subsequent cycles.
In this single-blind study the objective was to determine
the comparative efficacy and safety of granisetron compared
with the combination of high-dose metoclopramide and dex-
amethasone, which is commonly used to treat cisplatin-
induced nausea and vomiting. The anti-emetic efficacy of
each treatment in the first 24 h following cytostatic therapy
was not shown to be significantly different. Seventy percent
of patients receiving granisetron and 67% of patients receiv-
ing the metoclopramide and dexamethasone combination
were complete responders. Thirteen percent of patients in
granisetron group and 9% in the comparator group were
major responders with major efficacy of each treatment
group being 83% and 77% respectively. There were more
failures in the comparator gorup (10%) than in the graniset-
ron group (5%) although there was little difference in the
number of minor responders in either group. Thus both
preparations produced effective control of symptoms during
the first 24-h period. Granisetron also appears to have
efficacy in resolving or improving symptoms of breakthrough
nausea and vomiting. Of 30 patients who required an addi-
I A FZZI LN,14-M=- -1 I iZZA I I rzzi
l180 B. CHEVALLIER
tional dose of granisetron 87% responded in that their
symptoms resolved or improved. It seems, therefore, that
granisetron is useful, not only for the prophylaxis of
cytostatic-induced emesis, but also for its treatment.
In terms of the time to first symptoms of nausea or
vomiting there was also no significant difference between the
two groups, and there was no difference between the two
treatment groups when assessed for global efficacy by either
the patient or the clinician.
A proportion of patients in both treatment groups
remained free from further nausea or vomiting in the 6 days
following chemotherapy, whereas 36% of granisetron-treated
patients and 47% of comparator-treated patients remained
complete responders for the whole study period. It is difficult
to draw any firm conclusions about this observation which
may indicate that both treatments offer some protection
against emesis beyond the day of chemotherapy.
The results of this study show that granisetron has a good
safety profile with no serious granisetron-related adverse
effects. The commonest adverse event was headache which
was usually mild and resolved either spontaneously or with
mild analgesia. Conversely the use of dopamine antagonists
is known to be associated with a number of undesirable side
effects as was seen in this study where 13 extrapyramidal
reactions were reported, one of which was serious. This
particular problem has been reported as occurring in up to
30% of patients taking dopamine antagonists (Kris et al.,
1983). The effect is seen most frequently in younger patients
and with increasing doses, precluding the use of these drugs
at high doses for long periods of time (Kris et al., 1983). This
effect can be very distressing to the patient and may itself
require treatment, adding further complication to an already
cumbersome administration schedule. Granisetron does not
cause extrapyramidal symptoms. This is related to the fact
that it is a highly selective 5-HT3 receptor antagonist and
that it has no interaction with the dopamine receptor.
Indeed, it has little or no interaction with many other recep-
tor sites (Bermudez et al., 1988).
In addition, somnolence which was seen in 5.1% of
comparator-treated patients was only observed in one patient
(0.7%) treated with granisetron. Drowsiness is an undesirable
side effect as patients may be unable to drive home after
therapy and have to be escorted or remain in the clinic.
Diarrhoea also occurred significantly more frequently in the
comparator group compared with the granisetron group.
In conclusion, granisetron, when given as a convenient
single 5-min infusion (40,ug kg-', i.v.) provided antiemetic
protection comparable to that given by standard anti-emetic
regimens, with the significant advantage of simplicity of
administration. Granisetron is also safe to administer and is
not associated with extrapyramidal effects which were
associated with the comparator regimen. In addition, patients
experienced significantly less side effects such as diarrhoea
and somnolence with granisetron compared with the com-
parator.
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